{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:02:09Z","timestamp":1791849729912,"version":"4.3.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"De Merel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Antihypertensive drugs are among the most prescribed drugs during pregnancy. Methyldopa, labetalol, and nifedipine have been perceived safe to use during pregnancy and are therefore recommended in international guidelines for treatment of hypertension. In this review, we provide a complete overview of what is known on the pharmacokinetics (PK) of the antihypertensive drugs methyldopa, labetalol, and nifedipine throughout pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was performed to retrieve studies on the PK of methyldopa, labetalol, and nifedipine used throughout pregnancy. The search was restricted to English and original studies. The systematic search was conducted on July 27, 2021, in Embase, Medline Ovid, Web of Science, Cochrane Library, and Google Scholar. Keywords were methyldopa, labetalol, nifedipine, pharmacokinetics, pregnancy, and placenta.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1459 unique references were identified of which title and abstract were screened. Based on this screening, 67 full-text papers were assessed, to retain 30 PK studies of which 2 described methyldopa, 12 labetalol, and 16 nifedipine. No fetal accumulation is found for any of the antihypertensive drugs studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We conclude that despite decades of prescribing methyldopa, labetalol, and nifedipine throughout pregnancy, descriptions of their PK during pregnancy are hampered by a large heterogeneity in the low number of available studies. Aiming for evidence-based and personalized dosing of antihypertensive medication in the future, further studies on the relationship of both PK and pharmacodynamics (including the optimal blood pressure targeting) during pregnancy and pregnancy-related pathology are urgently needed to prevent undertreatment, overtreatment, and side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-022-03382-3","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T23:30:25Z","timestamp":1663198225000},"page":"1763-1776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review"],"prefix":"10.1007","volume":"78","author":[{"given":"Dylan","family":"van de Vusse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Schoenmakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Flint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Allegaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0674-7765","authenticated-orcid":false,"given":"Jorie","family":"Versmissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"key":"3382_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004365","volume":"4","author":"A Lupattelli","year":"2014","unstructured":"Lupattelli A, Spigset O, Twigg MJ, Zagorodnikova K, Mardby AC, Moretti ME, Drozd M, Panchaud A, Hameen-Anttila K, Rieutord A, Gjergja Juraski R, Odalovic M, Kennedy D, Rudolf G, Juch H, Passier A, Bjornsdottir I, Nordeng H (2014) Medication use in pregnancy: a cross-sectional, multinational web-based study. BMJ Open 4:e004365","journal-title":"BMJ Open"},{"key":"3382_CR2","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1053\/j.semperi.2015.08.002","volume":"39","author":"M Ayad","year":"2015","unstructured":"Ayad M, Costantine MM (2015) Epidemiology of medications use in pregnancy. Semin Perinatol 39:508\u2013511","journal-title":"Semin Perinatol"},{"key":"3382_CR3","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1067\/mob.2003.223","volume":"188","author":"DD Glover","year":"2003","unstructured":"Glover DD, Amonkar M, Rybeck BF, Tracy TS (2003) Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J Obstet Gynecol 188:1039\u20131045","journal-title":"Am J Obstet Gynecol"},{"key":"3382_CR4","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/pds.3641","volume":"23","author":"L Cea Soriano","year":"2014","unstructured":"Cea Soriano L, Bateman BT, Garcia Rodriguez LA, Hernandez-Diaz S (2014) Prescription of antihypertensive medications during pregnancy in the UK. Pharmacoepidemiol Drug Saf 23:1051\u20131058","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3382_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jacc.2018.10.075","volume":"73","author":"DG Halpern","year":"2019","unstructured":"Halpern DG, Weinberg CR, Pinnelas R, Mehta-Lee S, Economy KE, Valente AM (2019) Use of medication for cardiovascular disease during pregnancy: JACC state-of-the-art review. J Am Coll Cardiol 73:457\u2013476","journal-title":"J Am Coll Cardiol"},{"key":"3382_CR6","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/bcp.12685","volume":"80","author":"MM De Sousa","year":"2015","unstructured":"De Sousa MM, Hirt D, Urien S, Valade E, Bouazza N, Foissac F, Blanche S, Treluyer JM, Benaboud S (2015) Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. Br J Clin Pharmacol 80:1031\u20131041","journal-title":"Br J Clin Pharmacol"},{"key":"3382_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0889-8545(05)70317-X","volume":"24","author":"WF Rayburn","year":"1997","unstructured":"Rayburn WF, Farmer KC (1997) Off-label prescribing during pregnancy. Obstet Gynecol Clin North Am 24:471\u2013478","journal-title":"Obstet Gynecol Clin North Am"},{"key":"3382_CR8","doi-asserted-by":"crossref","unstructured":"Carbonne B, Winer N (2015) [Off-label treatments in obstetrics: tocolysis with calcium channel blockers]. Traitements hors AMM en obstetrique : tocolyse par les inhibiteurs calciques. Introduction. J Gynecol Obstet Biol Reprod (Paris) 44:295\u20136","DOI":"10.1016\/j.jgyn.2015.01.014"},{"key":"3382_CR9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jama.2021.1683","volume":"325","author":"SA Rasmussen","year":"2021","unstructured":"Rasmussen SA, Jamieson DJ (2021) Pregnancy, postpartum care, and COVID-19 vaccination in 2021. JAMA 325:1099\u20131100","journal-title":"JAMA"},{"key":"3382_CR10","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1001\/jama.2021.1865","volume":"325","author":"DW Bianchi","year":"2021","unstructured":"Bianchi DW, Kaeser L, Cernich AN (2021) Involving pregnant individuals in clinical research on COVID-19 vaccines. JAMA 325:1041\u20131042","journal-title":"JAMA"},{"key":"3382_CR11","doi-asserted-by":"crossref","unstructured":"Kazma JM, Van Den Anker J, Ahmadzia HK (2021) Pharmacoethics and pregnancy: overcoming the therapeutic orphan stigma. Br J Clin Pharmacol","DOI":"10.22541\/au.163251968.89310521\/v1"},{"key":"3382_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002160","volume":"13","author":"G Pariente","year":"2016","unstructured":"Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G (2016) Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med 13:e1002160","journal-title":"PLoS Med"},{"key":"3382_CR13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/sj.clpt.6100126","volume":"81","author":"MA Andrew","year":"2007","unstructured":"Andrew MA, Easterling TR, Carr DB, Shen D, Buchanan ML, Rutherford T, Bennett R, Vicini P, Hebert MF (2007) Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin Pharmacol Ther 81:547\u2013556","journal-title":"Clin Pharmacol Ther"},{"key":"3382_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/cpt.770","volume":"103","author":"AA Westin","year":"2018","unstructured":"Westin AA, Brekke M, Molden E, Skogvoll E, Castberg I, Spigset O (2018) Treatment With antipsychotics in pregnancy: changes in drug disposition. Clin Pharmacol Ther 103:477\u2013484","journal-title":"Clin Pharmacol Ther"},{"key":"3382_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2174\/1381612825666190320135137","volume":"25","author":"A Dallmann","year":"2019","unstructured":"Dallmann A, Mian P, Van den Anker J, Allegaert K (2019) Clinical pharmacokinetic studies in pregnant women and the relevance of pharmacometric tools. Curr Pharm Des 25:483\u2013495","journal-title":"Curr Pharm Des"},{"key":"3382_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/bdd.2081","volume":"38","author":"VK Jogiraju","year":"2017","unstructured":"Jogiraju VK, Avvari S, Gollen R, Taft DR (2017) Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations. Biopharm Drug Dispos 38:426\u2013438","journal-title":"Biopharm Drug Dispos"},{"key":"3382_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40265-014-0187-7","volume":"74","author":"CM Brown","year":"2014","unstructured":"Brown CM, Garovic VD (2014) Drug treatment of hypertension in pregnancy. Drugs 74:283\u2013296","journal-title":"Drugs"},{"key":"3382_CR18","first-page":"555","volume":"49","author":"ED Gallery","year":"1995","unstructured":"Gallery ED (1995) Hypertension in pregnancy. Practical management recommendations Drugs 49:555\u2013562","journal-title":"Practical management recommendations Drugs"},{"key":"3382_CR19","first-page":"1","volume":"3","author":"A Mammaro","year":"2009","unstructured":"Mammaro A, Carrara S, Cavaliere A, Ermito S, Dinatale A, Pappalardo EM, Militello M, Pedata R (2009) Hypertensive disorders of pregnancy. J Prenat Med 3:1\u20135","journal-title":"J Prenat Med"},{"key":"3382_CR20","doi-asserted-by":"crossref","unstructured":"Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, Asztalos E, Murphy KE, Menzies J, Sanchez J, Gafni A, Helewa M, Hutton E, Koren G, Lee SK, Logan AG, Ganzevoort W, Welch R, Thornton JG, Moutquin JM (2016)\u00a0Group* CS.\u00a0The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): is severe hypertension just an elevated blood pressure? Hypertension\u00a068:1153\u201359","DOI":"10.1161\/HYPERTENSIONAHA.116.07862"},{"key":"3382_CR21","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1161\/HYPERTENSIONAHA.112.196352","volume":"60","author":"M Bullo","year":"2012","unstructured":"Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD (2012) Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 60:444\u2013450","journal-title":"Hypertension"},{"key":"3382_CR22","doi-asserted-by":"crossref","unstructured":"Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall DR, Warren CE, Adoyi G, Ishaku S (2018)\u00a0International Society for the Study of Hypertension in P.\u00a0Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension\u00a072:24\u201343","DOI":"10.1161\/HYPERTENSIONAHA.117.10803"},{"key":"3382_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.4103\/IJCIIS.IJCIIS_33_17","volume":"7","author":"MTC Lam","year":"2017","unstructured":"Lam MTC, Dierking E (2017) Intensive care unit issues in eclampsia and HELLP syndrome. Int J Crit Illn Inj Sci 7:136\u2013141","journal-title":"Int J Crit Illn Inj Sci"},{"key":"3382_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1542\/peds.2007-2822","volume":"122","author":"CM Burns","year":"2008","unstructured":"Burns CM, Rutherford MA, Boardman JP, Cowan FM (2008) Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycemia. Pediatrics 122:65\u201374","journal-title":"Pediatrics"},{"key":"3382_CR25","first-page":"97","volume":"38","author":"O Stomnaroska","year":"2017","unstructured":"Stomnaroska O, Petkovska E, Jancevska S, Danilovski D (2017) Neonatal hypoglycemia: risk factors and outcomes. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 38:97\u2013101","journal-title":"Pril (Makedon Akad Nauk Umet Odd Med Nauki)"},{"key":"3382_CR26","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/1471-0528.12678","volume":"121","author":"RH Xie","year":"2014","unstructured":"Xie RH, Guo Y, Krewski D, Mattison D, Walker MC, Nerenberg K, Wen SW (2014) Beta-blockers increase the risk of being born small for gestational age or of being institutionalised during infancy. BJOG 121:1090\u20131096","journal-title":"BJOG"},{"key":"3382_CR27","doi-asserted-by":"crossref","unstructured":"Meidahl Petersen K, Jimenez-Solem E, Andersen JT, Petersen M, Brodbaek K, Kober L, Torp-Pedersen C, Poulsen HE (2012) beta-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open 2","DOI":"10.1136\/bmjopen-2012-001185"},{"key":"3382_CR28","doi-asserted-by":"crossref","unstructured":"Pariente G, Leibson T, Carls A, Adams-Webber T (2016) Pregnancy-associated changes in pharmacokinetics: a systematic review. journals.plos.org","DOI":"10.1371\/journal.pmed.1002160"},{"key":"3382_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj1290001","volume":"129","author":"WY Au","year":"1972","unstructured":"Au WY, Dring LG, Grahame-Smith DG, Isaac P, Williams RT (1972) The metabolism of 14 C-labelled -methyldopa in normal and hypertensive human subjects. Biochem J 129:1\u201310","journal-title":"Biochem J"},{"key":"3382_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/j.1875-9114.1983.tb03252.x","volume":"3","author":"EP MacCarthy","year":"1983","unstructured":"MacCarthy EP, Bloomfield SS (1983) Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy 3:193\u2013219","journal-title":"Pharmacotherapy"},{"key":"3382_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/j.1875-9114.1983.tb03252.x","volume":"3","author":"EP MacCarthy","year":"1983","unstructured":"MacCarthy EP, Bloomfield SS, Goodman RP (1983) Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy 3:193\u2013219","journal-title":"Pharmacotherapy"},{"key":"3382_CR32","doi-asserted-by":"crossref","unstructured":"Flenady V, Wojcieszek AM, Papatsonis DN, Stock OM, Murray L, Jardine LA, Carbonne B (2014) Calcium channel blockers for inhibiting preterm labour and birth. Cochrane Database Syst Rev\u00a0CD002255","DOI":"10.1002\/14651858.CD002255.pub2"},{"key":"3382_CR33","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/HJH.0000000000000069","volume":"32","author":"KA Al Khaja","year":"2014","unstructured":"Al Khaja KA, Sequeira RP, Alkhaja AK, Damanhori AH (2014) Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations. J Hypertens 32:454\u2013463","journal-title":"J Hypertens"},{"key":"3382_CR34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/NEJM199607253350407","volume":"335","author":"BM Sibai","year":"1996","unstructured":"Sibai BM (1996) Treatment of hypertension in pregnant women. N Engl J Med 335:257\u2013265","journal-title":"N Engl J Med"},{"key":"3382_CR35","doi-asserted-by":"crossref","unstructured":"Sorkin EM, Clissold SP, Brogden RN (1985) Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs 30:182\u2013274","DOI":"10.2165\/00003495-198530030-00002"},{"key":"3382_CR36","first-page":"205","volume":"143","author":"RP Buhs","year":"1964","unstructured":"Buhs RP, Beck JL, Speth OC, Smith JL, Trenner NR, Cannon PJ, Laragh JH (1964) The metabolism of methyldopa in hypertensive human subjects. J Pharmacol Exp Ther 143:205\u2013214","journal-title":"J Pharmacol Exp Ther"},{"key":"3382_CR37","unstructured":"T\u00f8nnesen HH (1996) Photostability of drugs and drug formulations. London: Taylor and Francis Ltd"},{"key":"3382_CR38","doi-asserted-by":"crossref","unstructured":"Quinney SK, Mohamed AN, Hebert MF, Haas DM, Clark S, Umans JG, Caritis SN, Li L (2012) A semi-mechanistic metabolism model of CYP3A substrates in pregnancy: predicting changes in midazolam and nifedipine pharmacokinetics. CPT Pharmacometrics Syst Pharmacol\u00a01","DOI":"10.1038\/psp.2012.5"},{"key":"3382_CR39","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1111\/bcp.13226","volume":"83","author":"GCDO Filgueira","year":"2017","unstructured":"Filgueira GCDO, Filgueira OAS, Carvalho DM, Marques MP, Mois\u00e9s ECD, Duarte G, Lanchote VL, Cavalli RC (2017) Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. Br J Clin Pharmacol 83:1571\u20131579","journal-title":"Br J Clin Pharmacol"},{"key":"3382_CR40","unstructured":"www.crd.york.ac.uk\/prospero"},{"key":"3382_CR41","unstructured":"prisma-statement.org"},{"key":"3382_CR42","doi-asserted-by":"crossref","unstructured":"Uematsu K, kobayahi E, Katsumoto E, Sugimoto M, Kawakami T, Terijima T, Maezawa K, Kizu J (2013) Umbilical cord blood concentrations of labetalol hydrochloride administered to patients with pregnancy induced hypertension, and subsequent neonatal findings. Hypertens Res Pregnancy 1:88\u201392","DOI":"10.14390\/jsshp.1.88"},{"key":"3382_CR43","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1365-2125.1978.tb04609.x","volume":"6","author":"HM Jones","year":"1978","unstructured":"Jones HM, Cummings AJ (1978) A study of the transfer of alpha-methyldopa to the human foetus and newborn infant. Br J Clin Pharmacol 6:432\u2013434","journal-title":"Br J Clin Pharmacol"},{"key":"3382_CR44","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1365-2125.1979.tb01022.x","volume":"8","author":"HM Jones","year":"1979","unstructured":"Jones HM, Cummings AJ, Setchell KD, Lawson AM (1979) A study of the disposition of alpha-methyldopa in newborn infants following its administration to the mother for the treatment of hypertension during pregnancy. Br J Clin Pharmacol 8:433\u2013440","journal-title":"Br J Clin Pharmacol"},{"key":"3382_CR45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00228-010-0896-0","volume":"67","author":"TMJP Carvalho","year":"2011","unstructured":"Carvalho TMJP, De Carvalho CR, Cunha SP, De Baraldi CO, Marques MP, Antunes NJ, Godoy ALPC, Lanchote VL (2011) Influence of gestational diabetes mellitus on the stereoselective kinetic disposition and metabolism of labetalol in hypertensive patients. Eur J Clin Pharmacol 67:55\u201361","journal-title":"Eur J Clin Pharmacol"},{"key":"3382_CR46","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/j.1552-4604.1993.tb01933.x","volume":"33","author":"T Saotome","year":"1993","unstructured":"Saotome T, Minoura S, Terashi K, Sato T, Echizen H, Ishizaki T (1993) Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis. J Clin Pharmacol 33:979\u2013988","journal-title":"J CLIN PHARMACOL"},{"key":"3382_CR47","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1365-2125.1983.tb01531.x","volume":"15","author":"PC Rubin","year":"1983","unstructured":"Rubin PC, Butters L, Kelman AW (1983) Labetalol disposition and concentration-effect relationships during pregnancy. Br J Clin Pharmacol 15:465\u2013470","journal-title":"BR J CLIN PHARMACOL"},{"key":"3382_CR48","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/0002-9378(90)90386-L","volume":"162","author":"RC Rogers","year":"1990","unstructured":"Rogers RC, Sibai BM, Whybrew WD (1990) Labetalol pharmacokinetics in pregnancy-induced hypertension. Am J Obstet Gynecol 162:362\u2013366","journal-title":"AM J OBSTET GYNECOL"},{"key":"3382_CR49","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/BF00544073","volume":"28","author":"NO Lunell","year":"1985","unstructured":"Lunell NO, Kulas J, Rane A (1985) Transfer of labetalol into amniotic fluid and breast milk in lactating women. Eur J Clin Pharmacol 28:597\u2013599","journal-title":"EUR J CLIN PHARMACOL"},{"key":"3382_CR50","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40262-013-0123-0","volume":"53","author":"JH Fischer","year":"2014","unstructured":"Fischer JH, Sarto GE, Hardman J, Endres L, Jenkins TM, Kilpatrick SJ, Jeong H, Geller S, Deyo K, Fischer PA, Rodvold KA (2014) Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. Clin Pharmacokinet 53:373\u2013383","journal-title":"Clin Pharmacokinet"},{"key":"3382_CR51","first-page":"573","volume":"47","author":"DW Boulton","year":"1999","unstructured":"Boulton DW, Dakers JM, Fawcett JP, Fiddes TM (1999) Transplacental distribution of labetalol stereoisomers at delivery [2]. Br J Clin Pharmacol 47:573\u2013574","journal-title":"Br J Clin Pharmacol"},{"key":"3382_CR52","doi-asserted-by":"crossref","unstructured":"Carvalho TMDJP, Cavalli RC, Marques MP, da Cunha SP, Baraldi CDO, Lanchote VL (2009) Stereoselective analysis of labetalol in human plasma by LC-MS\/MS: application to pharmacokinetics. Chirality\u00a021:738\u201344","DOI":"10.1002\/chir.20673"},{"key":"3382_CR53","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000157287","volume":"1","author":"M Nandakumaran","year":"1989","unstructured":"Nandakumaran M, Angelo-Khattar M, Ibrahim ME, Hathout H (1989) Transfer of labetalol in the perfused human placenta: an in vitro study. Med Princ Pract 1:81\u201385","journal-title":"MED PRINC PRACT"},{"key":"3382_CR54","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/0002-9378(88)90491-7","volume":"159","author":"H Schneider","year":"1988","unstructured":"Schneider H, Proegler M (1988) Placental transfer of \u03b2-adrenergic antagonists studied in an in vitro perfusion system of human placental tissue. Am J Obstet Gynecol 159:42\u201347","journal-title":"AM J OBSTET GYNECOL"},{"key":"3382_CR55","doi-asserted-by":"crossref","unstructured":"Nylund L, Lunell NO, Lewander R (1984) Labetalol for the treatment of hypertension in pregnancy: pharmakokinetics and effects on the uteroplacental blood flow. Acta Obstetricia et","DOI":"10.3109\/00016348409157127"},{"key":"3382_CR56","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5414\/CP202215","volume":"53","author":"MA Ter Laak","year":"2015","unstructured":"Ter Laak MA, Roos C, Touw DJ, Van Hattum PRM, Kwee A, Lotgering FK, Mol BWJ, Van Pampus MG, Porath MM, Spaanderman MEA, Van Der Post JAM, Papatsonis DNM, Van TVNE (2015) Pharmacokinetics of nifedipine slow-release tablets during sustained tocolysis. Int J Clin Pharmacol Ther 53:84\u201391","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3382_CR57","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/00006250-199011000-00016","volume":"76","author":"JP Pirhonen","year":"1990","unstructured":"Pirhonen JP, Erkkola RU, Ekblad UU, Nyman L (1990) Single dose of nifedipine in normotensive pregnancy: nifedipine concentrations hemodynamic responses, and uterine and fetal flow velocity waveforms. Obstet Gynecol 76:807\u2013811","journal-title":"OBSTET GYNECOL"},{"key":"3382_CR58","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/01.mjt.0000209679.76335.df","volume":"14","author":"DNM Papatsonis","year":"2007","unstructured":"Papatsonis DNM, Bos JM, Van Geijn HP, Lok CAR, Dekker GA (2007) Nifedipine pharmacokinetics and plasma levels in the management of preterm labor. Am J Ther 14:346\u2013350","journal-title":"Am J Ther"},{"key":"3382_CR59","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1471-0528.2007.01630.x","volume":"115","author":"AL Silberschmidt","year":"2008","unstructured":"Silberschmidt AL, K\u00fchn-Velten WN, Juon AM, Zimmermann R, Von Mandach U (2008) Nifedipine concentration in maternal and umbilical cord blood after nifedipine gastrointestinal therapeutic system for tocolysis. BJOG Int J Obstet Gynaecol 115:480\u2013485","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"3382_CR60","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3109\/14767058.2011.583700","volume":"25","author":"DM Haas","year":"2012","unstructured":"Haas DM, Quinney SK, McCormick CL, Jones DR, Renbarger JL (2012) A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic. J Matern -Fetal Neonatal Med 25:419\u2013423","journal-title":"J Matern -Fetal Neonatal Med"},{"key":"3382_CR61","first-page":"231","volume":"11","author":"AK Manninen","year":"1991","unstructured":"Manninen AK, Juhakoski A (1991) Nifedipine concentrations in maternal and umbilical serum, amniotic fluid, breast milk and urine of mothers and offspring. Int J Clin Pharmacol Res 11:231\u2013236","journal-title":"INT J CLIN PHARMACOL RES"},{"key":"3382_CR62","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3109\/10641959809072241","volume":"17","author":"AK Poranen","year":"1998","unstructured":"Poranen AK, Nurmi H, Malminiemi K, Ekblad U (1998) Vasoactive effects and placental transfer of nifedipine, celiprolol, and magnesium sulfate in the placenta perfused in vitro. Hypertens Pregnancy 17:93\u2013102","journal-title":"Hypertens Pregnancy"},{"key":"3382_CR63","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/0002-9378(89)90909-5","volume":"161","author":"IJE Ferguson","year":"1989","unstructured":"Ferguson IJE, Schutz T, Pershe R, Stevenson DK, Blaschke T (1989) Nifedipine pharmacokinetics during preterm labor tocolysis. Am J Obstet Gynecol 161:1485\u20131490","journal-title":"AM J OBSTET GYNECOL"},{"key":"3382_CR64","first-page":"275","volume":"30","author":"DM Haas","year":"2013","unstructured":"Haas DM, Quinney SK, Clay JM, Renbarger JL, Hebert MF, Clark S, Umans JG, Caritis SN (2013) Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. Am J Perinatol 30:275\u2013282","journal-title":"Am J Perinatol"},{"key":"3382_CR65","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/j.1875-9114.1992.tb04505.x","volume":"12","author":"RR Prevost","year":"1992","unstructured":"Prevost RR, Akl SA, Whybrew WD, Sibai BM (1992) Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. Pharmacotherapy 12:174\u2013177","journal-title":"Pharmacotherapy"},{"key":"3382_CR66","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jchromb.2015.04.030","volume":"993\u2013994","author":"GCDO Filgueira","year":"2015","unstructured":"Filgueira GCDO, Filgueira OAS, Carvalho DM, Marques MP, Mois\u00e9s ECD, Duarte G, Lanchote VL, Cavalli RC (2015) Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women. J Chromatogr B Anal Technol Biomed Life Sci 993\u2013994:20\u201325","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"3382_CR67","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1080\/01443610701195009","volume":"27","author":"TZ Marin","year":"2007","unstructured":"Marin TZ, Meier R, Kraehenmann F, Burkhardt T, Zimmermann R (2007) Nifedipine serum levels in pregnant women undergoing tocolysis with nifedipine. J Obstet Gynaecol 27:260\u2013263","journal-title":"J Obstet Gynaecol"},{"key":"3382_CR68","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s40262-017-0594-5","volume":"57","author":"A Dallmann","year":"2018","unstructured":"Dallmann A, Ince I, Coboeken K, Eissing T, Hempel G (2018) A physiologically based pharmacokinetic model for pregnant women to predict the pharmacokinetics of drugs metabolized via several enzymatic pathways. Clin Pharmacokinet 57:749\u2013768","journal-title":"Clin Pharmacokinet"},{"key":"3382_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.5","volume":"1","author":"SK Quinney","year":"2012","unstructured":"Quinney SK, Mohamed AN, Hebert MF, Haas DM, Clark S, Umans JG, Caritis SN, Li L (2012) A semi-mechanistic metabolism model of CYP3A substrates in pregnancy: predicting changes in midazolam and nifedipine pharmacokinetics. CPT Pharmacometrics Syst Pharmacol 1:e2","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"3382_CR70","doi-asserted-by":"crossref","unstructured":"Ke C, You X, Lin C, Chen J, Guo G, Wu W, Ye L, Huang P (2021) Development of Physiologically based pharmacokinetic model for pregabalin to predict the pharmacokinetics in pediatric patients with renal impairment and adjust dosage regimens: PBPK model of pregabalin in pediatric patients with renal impairment. J Pharm Sci","DOI":"10.1016\/j.xphs.2021.10.026"},{"key":"3382_CR71","doi-asserted-by":"crossref","unstructured":"Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Unadkat JD (2012) A PBPK model to predict disposition of CYP3A-metabolized drugs in pregnant women: verification and discerning the site of CYP3A induction. CPT Pharmacometrics Syst Pharmacol\u00a01","DOI":"10.1038\/psp.2012.2"},{"issue":"Suppl 1","key":"3382_CR72","first-page":"S63","volume":"60","author":"N Chaphekar","year":"2020","unstructured":"Chaphekar N, Caritis S, Venkataramanan R (2020) Model-informed dose optimization in pregnancy. J Clin Pharmacol 60(Suppl 1):S63\u2013S76","journal-title":"J Clin Pharmacol"},{"key":"3382_CR73","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10928-020-09698-w","volume":"47","author":"K Abduljalil","year":"2020","unstructured":"Abduljalil K, Badhan RKS (2020) Drug dosing during pregnancy-opportunities for physiologically based pharmacokinetic models. J Pharmacokinet Pharmacodyn 47:319\u2013340","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"3382_CR74","doi-asserted-by":"crossref","unstructured":"Blundell C, Yi YS, Ma L, Tess ER, Farrell MJ, Georgescu A, Aleksunes LM, Huh D (2018) Placental drug transport-on-a-chip: a microengineered in vitro model of transporter-mediated drug efflux in the human placental barrier. Adv Healthc Mater 7","DOI":"10.1002\/adhm.201700786"},{"key":"3382_CR75","doi-asserted-by":"crossref","unstructured":"Seely EW, Ecker J (2011) Clinical practice. Chronic hypertension in pregnancy. N Engl J Med 365:439\u201346","DOI":"10.1056\/NEJMcp0804872"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03382-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03382-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03382-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T18:43:28Z","timestamp":1701024208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03382-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":75,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["3382"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03382-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"assertion":[{"value":"2 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}